SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is under selling pressure amid reports of engineering delays for its first foldable iPhone, compounded by a recent unfavorable court ruling in China regarding Siri patent infringement. While some investors are concerned about potential financial settlements and product momentum, others in the community are viewing the dip as a temporary overreaction and a buying opportunity.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense downward pressure driven by a bearish JPMorgan analyst downgrade and broader geopolitical uncertainty, fueling widespread investor debate over whether the stock is a falling knife or a long-term value play. The community is actively weighing the potential impact of a rumored SpaceX IPO, which many fear may siphon liquidity away from Tesla shares as investors rotate their capital into the upcoming space venture.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a volatile surge driven by high short interest and speculative retail interest, which has fueled a rapid short squeeze. While community members debate whether this is a sustainable recovery or an overextended rally, trading activity remains intense as participants monitor the impact of broader industry dynamics and high-stakes options flow.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant momentum as the CMS finalized 2027 Medicare Advantage payment rates at a 2.5% increase, coming in notably higher than market expectations. While bulls view this as a vital relief rally and a potential short squeeze catalyst, the community remains actively divided between those highlighting the company's long-term franchise strength and others concerned about ongoing regulatory pressure and utilization headwinds.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is experiencing significant market interest driven by mixed reactions to Lyme disease vaccine trial data and ongoing investor focus on the company's oncology pipeline and strategic cost-cutting measures. Community sentiment remains highly polarized, with active discussions centering on the company's ability to drive growth through M&A, the impact of patent cliffs, and skepticism regarding its recent market performance compared to peers.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are intensely focused on escalating tensions between the U.S. and Iran, with traders debating whether a last-minute diplomatic deal or a significant geopolitical conflict will drive the next move. Sentiment remains highly volatile as the community parses conflicting reports on the status of negotiations, leading many to adopt a cautious stance while others speculate on potential downside risks to the broader equity market.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is currently experiencing high volatility and speculative activity as traders react to conflicting headlines regarding a potential ceasefire in the Middle East and the uncertainty surrounding the closure of the Strait of Hormuz. Community sentiment is deeply divided, with many market participants debating the sustainability of recent price action while closely monitoring institutional hedging flow and geopolitical updates to navigate the ongoing market instability.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor interest and bullish momentum, largely driven by the announcement of a multi-billion dollar buyback of its stake in the Ireland Fab 34 facility, which signals strong manufacturing commitment and long-term foundry confidence. The community is actively debating the company's turnaround potential, with many traders focused on the stock's ability to maintain resilience and break through key resistance levels despite broader market volatility and geopolitical concerns.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

TSLL is drawing heavy interest from traders who are actively debating its volatility decay and mechanics as a levered instrument, with many closely monitoring technical price action and recent options activity for signs of a potential short-term bounce. The community is sharply divided between those positioning for a rip based on bullish chart patterns or Musk-related catalysts and others who view the stock primarily as a vehicle for aggressive derivative plays during market-wide momentum shifts.

Empire State Realty Trust, Inc. is a real estate investment trust, which engages in owning, managing, acquiring, and repositioning office and retail properties. It operates through the Real Estate and Observatory segments. The Real Estate segment includes ownership, management, operation, acquisition, repositioning, and disposition of real estate assets. The Observatory segment manages observatories at the Empire state building. The company was founded on July 29, 2011 and is headquartered in New York, NY.

Empire State Realty Trust Inc - Ordinary Shares - Class A

Empire State Realty Trust is trending as investors debate its significant undervaluation relative to the asset value of its iconic NYC property portfolio. The community is actively calling for strategic management changes, including potential asset sales and intensified share buybacks to address the stock's persistent discount.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving Average   - Time to Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Above 50-Day Moving Average - Time to Sell...

MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.</li><li>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.&nbsp;</li><li>The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.</li></ul> Barclays on Tuesday raised the firm's price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.<h2 class="st-heading-2">Pipeline Updates</h2>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026, Risser said.Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MGNX">MGNX stock</a> has gained more than 50% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/viking-ceo-sees-its-obesity-drug-beating-novo-wegovy-in-weight-loss/cZdozzNRI7l">Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 

Equity

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 


Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock

Barclays increased their price target on MacroGenics from $3.00 to $4.00 and gave the company an "overweight" rating in a research report on Tuesday...

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

MacroGenics (NASDAQ:MGNX - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of...

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates

BioLife Solutions (BLFS) delivered earnings and revenue surprises of +300.00% and +5.16%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has been given a consensus rating of "Hold" by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has...

MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

MGNX
Macrogenics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGNX News

MGNXMacrogenics Inc